Cover Image

Point of Care Diagnostics for Emerging Infectious Disease Threats (Market Analysis and Technical Considerations)

The World Health Organization has identified a group of diseases that are the world' s most pressing health problems. This represents an opportunity for test manufacturers, particularly in POC testing. Because of their ability to deliver fast results at the point of care, rapid testing is a focus area of healthcare providers and payors in infectious disease prevention. Kalorama Information has been reporting on the rapid test area for several years and has identified the segments with the fastest growth, and infectious disease has surfaced as one of those segments.

This report, Point of Care Diagnostics for Emerging Infectious Disease Threats (Market Analysis and Technical Considerations), examines this POC segment with a focus on new threats for which there are markets in the developing world and in developed countries.

A Unique Approach: Market and Technical Analysis

Tests can only be marketed if they can be manufactured and if they can function in the healthcare environment. Thus, this report also discusses the technical choices, possibilities and limitations to today' s POC tests especially when they are used in the developing world. Reagent issues, testing on strips, instrumented and non-instrumented tests are coved in this report. These factors will impact what tests will reach the market and how they will function.

An Opportunity For Test Makers

Infectious disease is a broad category, and in some disease areas, diagnostic companies already own market share. Increasingly hospitals and clinics are seeing new infectious disease threats and tests are being developed to assist them. Within the infectious disease testing market, this report details the opportunities that could be found when diseases of the developing world enter the healthcare system of the developed. This report provides market projections for point of care diagnostics in the developed and developing world for the following infectious diseases:

  • Chagas Disease, Rapid Test Market Forecast to 2015
  • Chikungunya, Rapid Test Market Forecast to 2015
  • Dengue Fever, Rapid Test Market Forecast to 2015
  • HIV, Rapid Test Market Current Size and Forecast to 2015
  • HPV, Rapid Test Market Current Size and Forecast to 2015
  • Leishmaniasis, Rapid Test Market Forecast to 2015
  • Onchocerciasis (River Blindness), Rapid Test Market Forecast to 2015
  • STDs, Rapid Test Market Current Size and Forecast to 2015
  • Tuberculosis, Rapid Test Market Forecast to 2015

In addition the report also provides:

  • The Overall Point of Care Diagnostics Market Statistics
  • Economics of Financial and International Programs
  • Company Profiles of Leaders in the POC Infectious Disease Market
  • Key Players in the Infectious Disease Rapid Test Market
  • Developed and Developing World Opportunities
  • Test Volumes in Developing Countries
  • Review of Test Products Currently on the Market
  • Climate, Water Use and Sample Prep Considerations
  • EMR and Connectivity Issues
  • Tests in Development
  • The Role of Drug Resistance
  • Disease Statistics
  • POC and Infrastructure Needs
  • Comparison of Test Modalities and Sample Collection Methods

Two Industry Experts Provide Unique Insights

Shara Rosen is Kalorama Information' s lead diagnostic industry analyst. She is the author of seven best-selling editions of The Worldwide Market for In Vitro Diagnostics, as well as scores of other titles on segments of the IVD Industry.

Brendan O' Farrell is the President of Diagnostic Consulting Network , a provider of OEM services to developers and manufacturers of rapid assays. Key services include contract rapid assay system development, custom reagent development, industry education and training and consulting services. Among the topics these experts discuss is the number of competitors who have been successful with efforts in developing countries.

The following companies are discussed in this report:

  • 3QBD
  • Abbott Diagnostics Access Bio, Inc.
  • Acon Laboratories, Inc./Innovacon
  • Akers Biosciences, Inc.
  • Akonni Biosystems Inc.
  • Alere
  • American Bionostica, Inc.
  • AT First Diagnostic LLC
  • Beckman Coulter Inc. Becton Dickinson
  • Bhat Bio-tech India (p) Ltd.
  • Biocan Diagnostics Inc.
  • bioLytical Laboratories
  • Biomagnetics Diagnostics Corp.
  • Bio-Manguinhos/FioCruz
  • bioMerieux
  • BioVei Incorporated
  • Burnet Institute
  • California Institute of Technology (Caltech)
  • CapitalBio Corporation
  • Catalysis Foundation for Health
  • Cellestis Ltd
  • Cepheid
  • Chembio Diagnostic Systems, Inc.
  • Clearbridge BioLoc
  • Clinoteck Diagnostics
  • Core Diagnostics
  • CTK Biotech Inc.
  • Diagnostics for All (DFA)
  • Diagnostics for the Real World (DRW)
  • DIALAB
  • DNA Medicine Institute (DMI)
  • Eiken Chemical Co., Ltd.
  • Enigma Diagnostics Limited
  • Epistem Plc
  • FK Biotecnologia
  • Guardian Technologies International
  • Hain Lifescience GmbH
  • Hema Diagnostic Systems (HDS)
  • i+MED Laboratories Company Limited
  • InBios International, Inc.
  • Ionian Technologies, Inc.
  • IQuum Inc.
  • Jal Innovation (S) Pte
  • LabNow
  • Lifeassay Diagnostics (Pty) Ltd
  • Linnodee Ltd.
  • LumiQuick Diagnostics, Inc.
  • J. Mitra & Co. Pvt Ltd
  • MP Biomedicals
  • MedMira Inc.
  • Micronics, Inc.
  • Microskia
  • Millennium Biotechnology, Inc. (MBI)
  • Omega Diagnostics Group PLC
  • Partec GmbH
  • PointCare Technologies, Inc.
  • QBC Diagnostics, Inc.
  • QuantuMDx Group
  • Premier Medical Corporation Limited
  • Princeton BioMeditech Corporation
  • Seventh Sense Biosystems, Inc.
  • Signature Mapping Medical Sciences, Inc.
  • Span Diagnostics Ltd.
  • Standard Diagnostics, Inc.
  • Tulip Group
  • VEDA.LAB
  • Veredus Laboratories Pte
  • WAMA Diagnostica
  • Zyomyx Inc.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Scope and Methodology
  • Emerging Market Trends, diseases and technologies
  • World Demand for Decentralized Testing for Infectious Diseases

CHAPTER TWO: COMMERCIALIZATION OF DECENTRALIZED TEST DEVICES FOR INFECTIOUS DISEASES

  • Overview
  • User Training and Support Services
  • Connectivity Supports Decentralized Testing
  • The Disease Burden
  • Drug Resistance Complicates the Test Landscape
  • An Unmet Need
  • Economics of Financial and International Programs
  • Conclusion

CHAPTER THREE: TECHNICAL CONSIDERATIONS

  • Overview
  • Reagent Issues
  • Instrumented or non-instrumented
  • Diagnostics on Paper Test Strips
  • The Promise of Decentralized Molecular Diagnostics
  • Wireless Communication
  • Miniaturization

CHAPTER FOUR: CHAGAS DISEASE

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER FIVE: CHIKUNGUNYA

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER SIX: DENGUE

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER SEVEN: HIV

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER EIGHT: HPV

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER NINE: LEISHMANIASIS

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER TEN: LEPTOSPIROSIS

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER ELEVEN: MALARIA

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER TWELVE: ONCHOCERCIASIS (RIVER BLINDNESS)

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER THIRTEEN: STDs

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future

CHAPTER FOURTEEN: TUBERCULOSIS

  • Introduction: Key Comment
  • Geographic Markets
  • International Programs
  • Status quo in testing
  • Players
  • Test technologies, now and future
Show More
Pricing
Get Notified
Email me when related reports are published